NCT01827137View on ClinicalTrials.gov

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

December 7, 2016

Study Completion Date

November 6, 2017

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

Galinpepimut-S

Galinpepimut-S admixed with the adjuvant Montanide following specified schedule

BIOLOGICAL

GM-CSF

subcutaneous injection

OTHER

Montanide

adjuvant

DRUG

lenalidomide

optional post-ASCT therapy

DRUG

bortezomib

optional post-ASCT therapy

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

Sellas Life Sciences Group

INDUSTRY

NCT01827137 - WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation | Biotech Hunter | Biotech Hunter